We found that the IC50 values of several anti-cancer drugs, including sapitinib (an EGFR inhibitor) and selumetinib (a MEK1/2 inhibitor), decreased in the high-TRPV4 group, indicating that patients exhibiting high TRPV4 expression levels may be relatively sensitive to these anti-cancer drugs. The gene discussed is MAP2K1; the disease is cancer.